available at www.sciencedirect.com journal homepage: www.europeanurology.com



Case Study of the Month



Retroperitoneal Malignant Solitary Fibrous Tumor of the Small Pelvis Causing Recurrent Hypoglycemia by Secretion of Insulin-like Growth Factor 2

Sigrid Wagner^{a,*}, Francesco Greco^a, Amir Hamza^a, Rashid M. Hoda^a, Hans Jürgen Holzhausen^b, Paolo Fornara^a

^a Department of Urology and Kidney Transplantation, Martin Luther University, Ernst Grube Str. 40, 06120 Halle, Saale, Germany ^b Institute of Pathology, Martin Luther University, Ernst Grube Str. 40, 06120 Halle, Saale, Germany

Article info

Article history: Accepted September 23, 2008 Published online ahead of print on October 1, 2008

Keywords: Solitary fibrous tumor Hypoglycemia Doege-Potter syndrome

europeanurology

1. Case report

A 28-yr-old patient suffered left flank pain, with grade 2 ectasia of the left kidney. The presumptive diagnosis of an extragonadal testicular tumor was established after a radiologic examination (abdominal computed tomography [CT] and positron emission tomography [PET] scan) (Fig. 1).

Because the testicular tumor markers were negative, we performed a biopsy of the retroperitoneal mass, which was suggestive of a mesenchymal tumor. Immunohistochemical studies were

Abstract

A 28-yr-old man presented with recurrent reduced consciousness, generalized seizures of unknown etiology, recurrent hypoglycemia, psychomotor retardation, and grade 2 ectasia of the left kidney. Abdominal computed tomography (CT) and positron emission tomography (PET) scans demonstrated a well-circumscribed suprapubic pelvic mass, measuring $18 \times 15 \times 11$ cm, with involvement of para-aortic lymph nodes and dilatation of the left ureter suggestive of an extragonadal testicular tumor.

We excised the tumor by laparotomy, and it was confirmed to be a solitary fibrous tumor (SFT). After surgery and R0 tumor resection, the patient had no further evidence of hypoglycemia or of recurrence. © 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.

* Corresponding author. Department of Urology and Kidney Transplantation, Martin Luther University, Ernst Grube Str. 40, 06120 Halle, Saale, Germany. E-mail address: sigrid.wagner@medizin.uni-halle.de (S. Wagner).

> strongly positive for vimentin; positive for factor 8 expression in capillary vessels but negative in tumor cells; positive for clone MIB-1 in only 2–3% of cells; and negative for calretinin, CD21, CD34, S100, epithelial membrane antigen (EMA), desmin, smooth muscle actin (SMA), myogenin, pancytokeratin, and CD117. The patient had episodes of severe hypoglycemia caused by insulin-like growth factors (IGFs) produced by this tumor.

> Because of the presumptive diagnosis of a hemangiopericytoma after biopsy of the retroperitoneal mass, our initial therapeutic approach was



Fig. 1 - Scan showing retroperitoneal mass with a radiologic diagnosis of hemangiopericytoma.



Fig. 2 – Intraoperative photo shows pelvic mass in situ with compression of the transverse colon and left ureter.

an intravenous infusion of two cycles of bevacizumab (Avastin: Genentech, San Francisco, CA, USA). After treatment, there was no evidence of any reduction in the tumor mass, so we performed a surgical resection (Fig. 2).

The definitive histologic report described a 1660 g tumor, measuring $18 \times 15 \times 11$ cm, with a homogenous cut surface and relatively homogenous white, red, and brown markings (Figs. 3 and 4), well encapsulated without evidence of invasion of




Fig. 3 – Gross photograph of excised mass measuring 18 \times 15 \times 11 cm and 1660 g. The tumor was well encapsulated without evidence of invasion of surrounding structures.




Fig. 4 - Cut surface of the tumor.




Fig. 5 – (a) Immunohistologic evidence of a diffuse membrane expression of CD99, and (b) cytoplasmatic expression of Bcl2. CD34 expression was focally positive.

surrounding structures. The pathologist diagnosed the tumor as a malignant solitary fibrous tumor (SFT) with R0 resection. Immunohistochemistry demonstrated diffuse membranous expression of CD99, cytoplasmatic expression of Bcl2, and expression of CD34 but no expression of EMA, CD31, HMB45, desmin, or SMA (Fig. 5).

2. Discussion

Malignant SFTs, described in the literature as the Doege-Potter syndrome, are often associated with hypoglycemia [1]. SFTs are rare tumors with a 12–13% rate of malignancy. Hypoglycemia is seen in <5% of cases. The associated tumors are large, with a high mitotic rate. The hypoglycemia is related to IGF 2 (IGF2) produced by the tumor [2,3]. The downstream oncogenic pathways of IGF2, however, are not clear. SFT cells secrete IGF2 and proliferate in serum-free medium, consistent with an IGF2/insulin receptor (IR) autocrine loop. The etiologic relevance of IGF2 is supported by expression of IR A (IRA), the isoform with high affinity for IGF2, in all SFTs.

IR activation plays an oncogenic role in SFTs [3]. The most frequently described locations for these tumors are the pleura, lung, pancreas, intestine, greater omentum, and uterus [4–8]. The differential diagnosis for SFT includes hemangiopericytoma, gastrointestinal stromal tumors (GIST), malignant mesothelioma, synovial sarcoma, leiomyomatous tumors, and granulosa-cell tumors.

Immunohistochemical studies revealed reactivity for CD34, CD99, and Bcl2 but no staining for desmin, EMA, HMB45, SMA, S100, or CD31, thus confirming the diagnosis of SFT. After surgical resection of the tumor, high-molecular-weight IGF2 was not detected in the serum, and the hypoglycemia resolved. Immunohistochemically, IGF2 was localized to the Golgi area of the tumor cells. These findings suggest that hypoglycemia in this patient was caused by the overexpression of IGF2 by the SFT cells. Although SFT is typically associated with a favorable prognosis, a close follow-up is recommended because of limited information on its longterm behavior.

Conflicts of interest: The authors have nothing to disclose.

EU-ACME question

Please visit www.eu-acme.org/europeanurology to answer the below EU-ACME question on-line (the EU-ACME credits will then be attributed automatically).

Question:


What were the reasons for hypoglycemia in this patient?

- A. Paraneoplastic syndrome.
- B. High levels of circulated insulin-like growth factor 2 (IGF2).
- C. High mitotic rate of spindle cells.
- D. Expression of CD34 by tumor cells.

References

- Bongiovanni M, Viberti L, Pecchioni C, et al. Steroid hormone receptor in pleural solitary fibrous tumors and CD34+ progenitor stromal cells. J Pathol 2002;198:252–7.
- [2] Zafar H, Takimoto CH, Weiss G. Doege-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor. Med Oncol 2003;20:403–8.
- [3] Li Y, Chang Q, Rubin BP, et al. Insulin receptor activation in solitary fibrous tumors. J Pathol 2007;21:550–4.
- [4] Kameyama K, Okumura N, Kokado Y, Miyoshi K, Matsuoka T, Nakagawa T. Solitary fibrous tumor associated with non-islet cell tumor hypoglycemia. Ann Thorac Surg 2007;84:292–4.

- [5] Lucas CE, Ledgerwood AM. Malignant solitary fibrous tumor of the intestine with refractory hypoglycemia (Doege Potter syndrome). J Am Coll Surg 2006;203:398.
- [6] Nagase T, Adachi I, Yamada T, et al. Solitary fibrous tumor in the pelvic cavity with hypoglycemia: report of a case. Surg Today 2005;35:181–4.
- [7] Hirai A, Nakanishi R. Solitary fibrous tumor of the pleura with hypoglycemia associated with serum insulin-like growth factor II. J Thorac Cardiovasc Surg 2006; 132:713–4.
- [8] Balduyck B, Lauwers P, Govaert K, Hendriks J, De Maeseneer M, Van Schil P. Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report. J Thorac Oncol 2006;1:588–90.



The EUSP offers EAU members the following programmes:

- Scholarship 1 year for research
- Clinical Fellowship 6 weeks to 3 months
- Short Term Visit 2 to 3 weeks
- Visiting Professor

Application for the various EUSP programmes can be submitted online. Please visit www.uroweb.org or go directly to http://www.uroweb.org/professional-resources

European Association of Urology